Please login to the form below

Not currently logged in
Email:
Password:

Ranbaxy

This page shows the latest Ranbaxy news and features for those working in and with pharma, biotech and healthcare.

Nearly half of all clinical trials not published

Nearly half of all clinical trials not published

Drilling down into the data provides a mixed picture for the pharma industry - at one end of the scale is Ranbaxy, which has published no results for any of the 35

Latest news

More from news
Approximately 6 fully matching, plus 92 partially matching documents found.

Latest Intelligence

  • Pharma deals in April 2015 Pharma deals in April 2015

    The acquisition of this portfolio with sales of INR 150 Crores, will help Dr Reddy's maintain a competitive edge with fellow Indian rival Sun Pharmaceuticals, following its acquisition of Ranbaxy

  • Allergan and taking a specialised approach Allergan and taking a specialised approach

    But for the likes of GSK, Novartis and Lilly with their asset swap agreement, Forest Laboratories and its acquisition of Actavis, and the various dealings at Merck &Co, BMS, Ranbaxy and

  • Pharma deals during April 2014 Pharma deals during April 2014

    for its stake in Ranbaxy in 2008, not to mention the 2013 $500m payment to the US authorities to settle 7 felony charges. ... is rumoured that a solution will be to replace the Ranbaxy brand with the Sun Pharma moniker at least in the US.

  • Deal Watch table for April 2014 Deal Watch table for April 2014

    Ranbaxy Laboratories/ Sun Pharmaceuticals. Acquisition. Generics including Lipitor, Nexium, Diovan. 3, 200.

  • Positive prospects for pharma in Latin America Positive prospects for pharma in Latin America

    Since 2008, more foreign companies such as Takeda, Daiichi Ranbaxy and others have been allowed to set operations in the country, increasing competition and consolidation.

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Competition from within

    Teva (Israel), CSL (Australia) and Aspen (South Africa) are notable exceptions, with the Indian generic giants Sun and Ranbaxy - which have since merged - the only representation from the ‘BRIC’ markets (Brazil,

  • Exploring MINT: Part 3 - Nigeria

    as Indian Cipla, Hetero and Ranbaxy among those supplying low-cost generic ARVs to African governments.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

Alzheimers incidence
A roadmap to the successful treatment of Alzheimer’s disease
Building on past research to learn more about the disease and how to treat it...
Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...

Infographics